Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Summary

The main objective of the trial is to evaluate, how long an antipsychotic relapse-prevention should be continued and to which time a patient with schizophrenia is protected enough, so that a withdrawal or reduction of the medication seems appropriate. Relapse is defined as primary outcome.

Conditions

• Schizophrenia
• Schizophrenia and Disorders With Psychotic Features
• Schizoaffective Disorders

Interventions

DRUG

Olanzapine

DRUG

Amisulpride

DRUG

Risperidone

DRUG

Haloperidol

DRUG

Quetiapine

DRUG

Perphenazine

DRUG

Sulpiride

DRUG

bromperidol

DRUG

Zuclopenthixol

DRUG

Thioridazine

DRUG

Paliperidone

DRUG

Ziprasidone

DRUG

Benperidol

DRUG

Fluspirilene

DRUG

Pimozide

DRUG

Perazine

DRUG

Fluphenazine

DRUG

Flupentixole

DRUG

Sertindole

Sponsors & Collaborators

• Technical University of Munich

  lead OTHER

Principal Investigators

• Stefan Leucht, Professor · Klinikum rechts der Isar

• Markus Dold, MD · Klinikum rechts der Isar

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-02-01

Primary Completion

2016-06-22

Completion

2016-06-22

Countries

• Germany

Study Locations